Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Go back to Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 58.44 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.44 | 52 Week High | $3.48 | |||
| Open | $58.44 | 52 Week Low | $0.80 | |||
| Day High | $58.44 | P/E | N/A | |||
| Day Low | $58.44 | EPS | $-1.54 | |||
| Volume | 5 | |||||
